Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Conditions: Acute Biphenotypic Leukemia; Acute Leukemia; Acute Leukemia of Ambiguous Lineage; Acute Lymphoblastic Leukemia; Acute Undifferentiated Leukemia; Allogeneic Hematopoietic Stem Cell Transplantation Recipient; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blasts Under 25 Percent of Bone Marrow Nucleated Cells; Blasts Under 5 Percent of Bone Marrow Nucleated Cells; Mixed Phenotype Acute Leukemia; Myelodysplastic Syndrome With Excess Blasts-1; Myelodysplastic Syndrome With Excess Blasts-2 Interventions: Radiation: Total-Body Irradiation; Drug: Thiotepa; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Busulfan; Biological: Allogeneic Hematopoietic Stem Cell Transplantation (unmanipulated T cell replete BM); Drug: Tacrolimus; Drug: Methotrexate; Biological: Alloge neic Hematopoietic Stem Cell Transplantation (naive T cell-depleted PBSC) Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer in Young Adults | Children | Chronic Leukemia | Leukemia | Methotrexate | Prograf | Research | Stem Cell Therapy | Stem Cells | Tacrolimus | Transplants